In a market sector that is constantly evolving, which is leading to reduced costs and newer tech being announced seemingly in an endless stream, the online space is becoming more widely available to people around the world than ever before. One of the markets adopting these changes in tech faster than anyone else in the world is India. This had been seen recently in the rapid rise of the social media platform TikTok before the ban – with a population size of over 1.3 billion, the platform was able to capture almost 120 million active users, a number that’s hard for any to look past.
But social media hasn’t been the only space for growth. The Indian online betting industry has also experienced a huge growth in recent years, despite online gambling being technically illegal in the country. A number of sites that allow betting on sports in India already exist and, given the huge national interest in cricket and other sports, it’s no surprise that things could quickly be changing. India's relatively untapped audience is driving more and more attention and we're seeing regulatory changes in many parts of the world. The UK has recently decided to updated its gambling legislation, banning things such as credit card deposits. But with little online regulation or much in the way of ruleset for these operators within India, there is plenty of space to move around and feel things out. Alongside this, because there is little in the way of gambling infrastructure within the country, there's an opportunity for regulation to be developed along the way. Not only to best support the growing number of new players that will be involved but in order to also ensure the operators of these sites have some wiggle room too.
That isn’t to say there aren’t any challenges however – initial reports suggest that only 23 million people within India have the financial capabilities to bet online. But as with all countries that are quickly developing, this number is expected to rise very quickly as the middle-class population is expanding. Sure, the challenge of accessibility remains real for many potential players. It has been suggested that a little under half of the entire population are currently active on the internet. However, figures are suggesting that number is rising by up to 60 million each year, as shown by the the success of platforms such as TikTok. By the time operators have been able to build and establish themselves in the region the numbers may have already risen to a very healthy number to get things started extremely quickly.
There’s also cultural changes to consider. It's already happening across many parts of the world, such as many African countries where western ideologies are starting to take root, and the same might reveal to be true for India. If online betting is still a foreign concept, having new users to understand how to best approach it and to change attitude towards gambling is important in online betting really taking off. Despite the huge population, India is still an emerging market after all and still a market adjusting to the modern technological changes. Gambling is very much on its way towards legalisation with the sweeping acceptance however, and it may not be long until India is seen as one of the bigger primary gambling markets in the world with a core built around the sports betting industry.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.